pubmed-article:11207639 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0021294 | lld:lifeskim |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0728731 | lld:lifeskim |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0123707 | lld:lifeskim |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0683150 | lld:lifeskim |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0021665 | lld:lifeskim |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0443288 | lld:lifeskim |
pubmed-article:11207639 | lifeskim:mentions | umls-concept:C0127400 | lld:lifeskim |
pubmed-article:11207639 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:11207639 | pubmed:dateCreated | 2001-3-14 | lld:pubmed |
pubmed-article:11207639 | pubmed:abstractText | Preterm infants receiving dexamethasone for respiratory morbidity frequently suffer restricted growth. The aim of this study was to investigate the interactions between dexamethasone treatment regimen and circulating IGFBP-3 and IGF-I levels, and the associations between these variables and linear growth rate in preterm babies receiving dexamethasone for chronic lung disease of prematurity. | lld:pubmed |
pubmed-article:11207639 | pubmed:language | eng | lld:pubmed |
pubmed-article:11207639 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11207639 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11207639 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11207639 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11207639 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11207639 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11207639 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11207639 | pubmed:month | Feb | lld:pubmed |
pubmed-article:11207639 | pubmed:issn | 0300-0664 | lld:pubmed |
pubmed-article:11207639 | pubmed:author | pubmed-author:KnightD BDB | lld:pubmed |
pubmed-article:11207639 | pubmed:author | pubmed-author:BreierB HBH | lld:pubmed |
pubmed-article:11207639 | pubmed:author | pubmed-author:HardingJ EJE | lld:pubmed |
pubmed-article:11207639 | pubmed:author | pubmed-author:BloomfieldF... | lld:pubmed |
pubmed-article:11207639 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11207639 | pubmed:volume | 54 | lld:pubmed |
pubmed-article:11207639 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11207639 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11207639 | pubmed:pagination | 235-42 | lld:pubmed |
pubmed-article:11207639 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:meshHeading | pubmed-meshheading:11207639... | lld:pubmed |
pubmed-article:11207639 | pubmed:year | 2001 | lld:pubmed |
pubmed-article:11207639 | pubmed:articleTitle | Growth restriction in dexamethasone-treated preterm infants may be mediated by reduced IGF-I and IGFBP-3 plasma concentrations. | lld:pubmed |
pubmed-article:11207639 | pubmed:affiliation | Research Centre for Developmental Medicine and Biology, University of Auckland, New Zealand. | lld:pubmed |
pubmed-article:11207639 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11207639 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:11207639 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:11207639 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11207639 | lld:pubmed |